Oculis (NASDAQ:OCS) Shares Gap Up – Here’s What Happened
by Jessica Moore · The Cerbat GemOculis Holding AG (NASDAQ:OCS – Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $19.75, but opened at $21.81. Oculis shares last traded at $21.9250, with a volume of 84,402 shares traded.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on the company. Chardan Capital reiterated a “buy” rating and set a $51.00 price target on shares of Oculis in a report on Tuesday, November 11th. Lifesci Capital began coverage on shares of Oculis in a research report on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of Oculis in a research note on Friday, December 19th. They set an “overweight” rating and a $38.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $36.00 price target on shares of Oculis in a research note on Tuesday, November 11th. Finally, Bank of America cut their price target on shares of Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $41.50.
Get Our Latest Analysis on Oculis
Oculis Price Performance
The company has a quick ratio of 4.47, a current ratio of 4.47 and a debt-to-equity ratio of 0.02. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -8.72 and a beta of 0.31. The stock’s 50-day simple moving average is $19.82 and its 200 day simple moving average is $18.91.
Oculis (NASDAQ:OCS – Get Free Report) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. The business had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.23 million. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. On average, equities research analysts anticipate that Oculis Holding AG will post -2.09 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of OCS. Compagnie Lombard Odier SCmA grew its stake in shares of Oculis by 11.5% in the second quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company’s stock valued at $1,883,000 after buying an additional 10,000 shares in the last quarter. Woodline Partners LP boosted its holdings in Oculis by 65.8% during the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after acquiring an additional 33,265 shares during the period. Bank of America Corp DE boosted its holdings in Oculis by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after acquiring an additional 878 shares during the period. Geode Capital Management LLC grew its position in Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after acquiring an additional 6,384 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Oculis during the second quarter worth about $393,000. 22.30% of the stock is currently owned by hedge funds and other institutional investors.
About Oculis
Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.
Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.